AstraZeneca se confiesa: "Yo pago..."

.

Earlier this month, pharmaceutical powerhouse AstraZeneca announced that it would disclose all payments to healthcare providers in all countries where it has commercial activities.

The announcement, made by CEO Pascal Soriot, came at the annual meeting of investors.

Ver:

Dollar for docs test...& facts.

According to The Times of London, Mr. Soriot stated, “[There was] no reason for us not to disclose.” He went on to note, “It’s only a question of making sure we have the tools to do it in an efficient and indeed transparent manner. I think we should be able to do it soon,”alluding to the fact that the company has been thinking about this for awhile and has started to create systems to ensure smooth reporting.

Compiling all of this information will not be easy, as the company has commercial operations and/or local offices with marketing programs in more than 100 countries, with tens of thousands of employees engaged in commercial activities at the end of 2017.

Not all countries have the requirement for reporting because they often do not have the bandwidth to collect and maintain the data. In the United States, companies are obligated to report payments under the Physician Payments Sunshine Act. 

With respect to AstraZeneca, in 2016, the company paid U.S. doctors an estimated $54 million in general payments (typically includes speaking and consulting fees), as compared to about $260 million it paid doctors for research.
(...)

In 2011 AstraZeneca announced that they were no longer paying for travel by attendees to medical meetings this applied world wide. Several other companies followed suit and this year (2018) device associations in Europe, Asia and Middle East member companies discontinued directly paying for attendee travel to medical meetings.(Más)